Εμφανίζονται 1 - 5 Αποτελέσματα από 5 για την αναζήτηση 'Alexander Fortuna (16797712)', χρόνος αναζήτησης: 0,01δλ Περιορισμός αποτελεσμάτων
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... ανά Stephanie Lheureux (16797697)

    Έκδοση 2025
    Άλλοι συγγραφείς:
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... ανά Stephanie Lheureux (16797697)

    Έκδοση 2025
    Άλλοι συγγραφείς:
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... ανά Stephanie Lheureux (16797697)

    Έκδοση 2025
    Άλλοι συγγραφείς:
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... ανά Stephanie Lheureux (16797697)

    Έκδοση 2025
    Άλλοι συγγραφείς:
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... ανά Stephanie Lheureux (16797697)

    Έκδοση 2025
    Άλλοι συγγραφείς:
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: